The endocannabinoid system in Huntington's disease.

  title={The endocannabinoid system in Huntington's disease.},
  author={Mar{\'i}a Ruth Pazos and Onintza Sagredo and Javier Fern{\'a}ndez-Ruiz},
  journal={Current pharmaceutical design},
  volume={14 23},
The hypokinetic profile of certain cannabinoid agonists becomes these compounds as promising medicines to attenuate the hyperkinesia that characterizes the first grades of Huntington's disease (HD) and that represents the major neurological abnormality in this disease. The fact that CB(1) receptors, the receptor type involved in motor effects of cannabinoid agonists, are significantly reduced in the basal ganglia during the progression of HD represents a convincing explanation for the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 38 extracted citations

Identification and characterization of Adenosine A 2 A heteromers in the CNS

Marc Brugarolas Campillos sota la direcció del Dr. Rafa Burillo
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…